Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2018 - 2026)

Collegium Pharmaceutical has reported Total Non-Current Liabilities for 5 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 37.54% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 37.54% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 6.13% from the prior year.
• Total Non-Current Liabilities was $1.7 billion for Q2 2026 at Collegium Pharmaceutical, up from $1.2 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.7 billion in Q2 2026, with the low at $947.9 million in Q4 2023.
• Average Total Non-Current Liabilities over 4 years is $1.3 billion, with a median of $1.2 billion recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 38.64% in 2024, then decreased 6.13% in 2025.
• Over 4 years, Total Non-Current Liabilities stood at $947.9 million in 2023, then surged by 38.64% to $1.3 billion in 2024, then decreased by 6.13% to $1.2 billion in 2025, then jumped by 38.01% to $1.7 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.7 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.